Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride pediatric functional constipation phase 3 study
2022-003221-22Phase 3
- Sponsor
- Takeda
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prucalopride in functional constipation (FC) (3 arms), sponsored by Takeda. Primary endpoint: Average change from baseline in number of spontaneous bowel movements per week.
02
Drugs
prucalopride
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on 2022-003221-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003221-22.